Alvarez et al. confirmed that the use of pegylated asparaginase (PEG-ASP), the drug with a longer half-life, is associated with a significant increase in the incidence of pancreatitis compared to the classical formulation of l-asparaginase (18% vs. 1.9%), probably due to prolonged asparagine depletion [11]. Here, ASPG is linked to pancreatitis.